The pharmaceutical industry's leading experts are gathering for the 2nd RNA-Targeted Drug Discovery Summit, marking a significant milestone in the pursuit of RNA-targeted therapeutics. This exclusive industry-focused conference brings together prominent researchers and developers from major pharmaceutical companies, biotechnology firms, and academic institutions to tackle the challenges in developing RNA-targeted small molecule drugs.
Advancing RNA-Targeted Therapeutic Development
The summit represents a crucial platform for addressing the complex challenges in RNA-targeted drug discovery. Researchers from Beth Israel Deaconess Medical Center, University of North Carolina, and Northwestern University will present cutting-edge insights into RNA structure, function, and its role in disease mechanisms. This fundamental understanding is essential for developing effective therapeutic interventions.
Industry leaders from Bristol-Myers Squibb, PTC Therapeutics, and Merck will share their expertise on identifying and validating viable RNA target sites. Their presentations will focus on practical approaches to overcome current limitations in RNA-targeted drug development.
Innovation in RNA-Protein Interactions
A significant portion of the conference will focus on novel approaches to targeting RNA through RNA-protein interactions and epitranscriptomics. Storm Therapeutics, Accent Therapeutics, and Gotham Therapeutics will present their pioneering work in this area, offering new perspectives on therapeutic intervention strategies.
Addressing Key Technical Challenges
Scientists from Pfizer and Novartis will lead discussions on overcoming critical technical hurdles in RNA-targeted drug development. These sessions will address:
- Small molecule binding optimization
- Selectivity enhancement strategies
- Drug-like property improvements
- Delivery system innovations
Transforming the Undruggable Landscape
The summit will showcase how companies like Anima Biotech, Arrakis Therapeutics, and Eli Lilly are working to reverse the traditional notion of RNA as an undruggable target. Their research demonstrates promising approaches to developing small molecule therapeutics that effectively target RNA, opening new possibilities for treating previously challenging diseases.
This comprehensive gathering of industry experts and academic leaders represents a significant step forward in RNA-targeted drug discovery, potentially revolutionizing the approach to developing new therapeutic agents for various diseases.
